---
document_datetime: 2025-12-29 09:37:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zolgensma.html
document_name: zolgensma.html
version: success
processing_time: 0.1339411
conversion_datetime: 2025-12-29 23:41:26.295536
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zolgensma

[RSS](/en/individual-human-medicine.xml/67310)

##### Authorised

This medicine is authorised for use in the European Union

onasemnogene abeparvovec Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zolgensma](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78758)
- [More information on Zolgensma](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zolgensma is a gene therapy medicine for treating spinal muscular atrophy, a serious condition of the nerves that causes muscle wasting and weakness.

It is intended for patients with inherited mutations affecting a gene known as *SMN1* , who have either been diagnosed with SMA type 1 (the most severe type) or have up to 3 copies of another gene known as *SMN2* .

Spinal muscular atrophy is rare, and Zolgensma was designated an 'orphan medicine' (a medicine used in rare diseases) on 19 June 2015.

Zolgensma contains the active substance onasemnogene abeparvovec.

Expand section

Collapse section

## How is Zolgensma used?

Zolgensma is given once as an infusion (drip) into a vein lasting about 1 hour. The infusion should take place in a clinic or hospital under the supervision of a doctor experienced in managing spinal muscular atrophy.

Before and after receiving the infusion, the patient will have a number of tests, including liver and blood tests, and will be given corticosteroid medicines to reduce the risk of side effects. The medicine can only be obtained with a prescription. For more information about using Zolgensma, see the package leaflet or contact your doctor or pharmacist.

## How does Zolgensma work?

Patients with spinal muscular atrophy have a defect in a gene known as *SMN1* , which the body needs to make a protein essential for the normal functioning of nerves that control muscle movements. The active substance in Zolgensma, onasemnogene abeparvovec, contains a functional copy of this gene. When injected, it passes into the nerves from where it provides the correct gene to make enough of the protein and thereby restore nerve function.

## What benefits of Zolgensma have been shown in studies?

A main study showed that Zolgensma reduces the need for artificial ventilation in babies with spinal muscular atrophy. In this study, 20 out of the 22 babies given Zolgensma were alive and breathing without a permanent ventilator after 14 months, when normally only a quarter of untreated patients would survive without needing a ventilator.

The study also showed that Zolgensma can help babies sit unaided for at least 30 seconds. 14 out of the 22 babies given Zolgensma were able to do so after 18 months, a milestone that is never achieved in untreated babies with severe forms of the disease.

## What are the risks associated with Zolgensma?

The most common side effects with Zolgensma are raised liver enzymes, injury to the liver (hepatotoxicity), low levels of blood platelets (thrombocytopenia), raised levels of troponin (a measure which indicates damage to the heart muscle), fever and vomiting.

For the full list of restrictions and side effects of Zolgensma, see the package leaflet.

## Why is Zolgensma authorised in the EU?

The main study of Zolgensma showed that a one-time infusion can improve survival in these patients and reduce the need for a permanent ventilator to breathe. It can also help them reach development milestones. As for its safety, the side effects of Zolgensma are considered manageable; the most common side effect in the study, raised liver enzymes, required treatment with a steroid. The European Medicines Agency therefore decided that Zolgensma's benefits are greater than its risks and it can be authorised for use in the EU.

Zolgensma was originally given 'conditional authorisation' because there was more evidence to come about the medicine. As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full authorisation.

## What measures are being taken to ensure the safe and effective use of Zolgensma?

The company that markets Zolgensma will provide educational materials to caregivers with information on how to use the medicine safely, the risks associated with the medicine and how to identify and report side effects. It will also conduct a study of the medicine's safety and effectiveness in the long-term.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zolgensma have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zolgensma are continuously monitored. Side effects reported with Zolgensma are carefully evaluated and any necessary actions taken to protect patients.

## Other information about Zolgensma

Zolgensma received a conditional marketing authorisation valid throughout the EU on 18 May 2020. This was switched to a full marketing authorisation on 17 May 2022.

Further information on Zolgensma can be found on the Agency's website: [ema.europa.eu/medicines/human/EPAR/zolgensma](/en/medicines/human/EPAR/zolgensma)

This overview was last updated in 08-2022.

Zolgensma : EPAR - Medicine overview

Reference Number: EMA/725800/2022

English (EN) (122.81 KB - PDF)

**First published:** 27/05/2020

**Last updated:** 17/03/2023

[View](/en/documents/overview/zolgensma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-749)

български (BG) (138.66 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/bg/documents/overview/zolgensma-epar-medicine-overview_bg.pdf)

español (ES) (112.28 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/es/documents/overview/zolgensma-epar-medicine-overview_es.pdf)

čeština (CS) (135.01 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/cs/documents/overview/zolgensma-epar-medicine-overview_cs.pdf)

dansk (DA) (113.51 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/da/documents/overview/zolgensma-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.35 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/de/documents/overview/zolgensma-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.53 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/et/documents/overview/zolgensma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (139.93 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/el/documents/overview/zolgensma-epar-medicine-overview_el.pdf)

français (FR) (113.47 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/fr/documents/overview/zolgensma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (133 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/hr/documents/overview/zolgensma-epar-medicine-overview_hr.pdf)

italiano (IT) (111.07 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/it/documents/overview/zolgensma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (148.63 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/lv/documents/overview/zolgensma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (132.41 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/lt/documents/overview/zolgensma-epar-medicine-overview_lt.pdf)

magyar (HU) (134.83 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/hu/documents/overview/zolgensma-epar-medicine-overview_hu.pdf)

Malti (MT) (136.14 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/mt/documents/overview/zolgensma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (113.02 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/nl/documents/overview/zolgensma-epar-medicine-overview_nl.pdf)

polski (PL) (136.59 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/pl/documents/overview/zolgensma-epar-medicine-overview_pl.pdf)

português (PT) (112.44 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/pt/documents/overview/zolgensma-epar-medicine-overview_pt.pdf)

română (RO) (131.57 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/ro/documents/overview/zolgensma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (134.59 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/sk/documents/overview/zolgensma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.21 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/sl/documents/overview/zolgensma-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.67 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/fi/documents/overview/zolgensma-epar-medicine-overview_fi.pdf)

svenska (SV) (110.46 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

17/03/2023

[View](/sv/documents/overview/zolgensma-epar-medicine-overview_sv.pdf)

Zolgensma : EPAR - Risk-management-plan

English (EN) (3.58 MB - PDF)

**First published:** 27/05/2020

**Last updated:** 11/07/2024

[View](/en/documents/rmp-summary/zolgensma-epar-risk-management-plan_en.pdf)

## Product information

Zolgensma : EPAR - Product information

English (EN) (556.7 KB - PDF)

**First published:** 27/05/2020

**Last updated:** 28/08/2025

[View](/en/documents/product-information/zolgensma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-129)

български (BG) (652.85 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/bg/documents/product-information/zolgensma-epar-product-information_bg.pdf)

español (ES) (628.15 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/es/documents/product-information/zolgensma-epar-product-information_es.pdf)

čeština (CS) (603.9 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/cs/documents/product-information/zolgensma-epar-product-information_cs.pdf)

dansk (DA) (599.57 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/da/documents/product-information/zolgensma-epar-product-information_da.pdf)

Deutsch (DE) (586.03 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/de/documents/product-information/zolgensma-epar-product-information_de.pdf)

eesti keel (ET) (580.81 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/et/documents/product-information/zolgensma-epar-product-information_et.pdf)

ελληνικά (EL) (952.16 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/el/documents/product-information/zolgensma-epar-product-information_el.pdf)

français (FR) (633.55 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/fr/documents/product-information/zolgensma-epar-product-information_fr.pdf)

hrvatski (HR) (651.28 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/hr/documents/product-information/zolgensma-epar-product-information_hr.pdf)

íslenska (IS) (603.37 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/is/documents/product-information/zolgensma-epar-product-information_is.pdf)

italiano (IT) (577.08 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/it/documents/product-information/zolgensma-epar-product-information_it.pdf)

latviešu valoda (LV) (622.46 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/lv/documents/product-information/zolgensma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (599.88 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/lt/documents/product-information/zolgensma-epar-product-information_lt.pdf)

magyar (HU) (617.74 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/hu/documents/product-information/zolgensma-epar-product-information_hu.pdf)

Malti (MT) (689.04 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/mt/documents/product-information/zolgensma-epar-product-information_mt.pdf)

Nederlands (NL) (626.72 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/nl/documents/product-information/zolgensma-epar-product-information_nl.pdf)

norsk (NO) (611.74 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/no/documents/product-information/zolgensma-epar-product-information_no.pdf)

polski (PL) (640.26 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/pl/documents/product-information/zolgensma-epar-product-information_pl.pdf)

português (PT) (596.79 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/pt/documents/product-information/zolgensma-epar-product-information_pt.pdf)

română (RO) (635.85 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/ro/documents/product-information/zolgensma-epar-product-information_ro.pdf)

slovenčina (SK) (640.61 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/sk/documents/product-information/zolgensma-epar-product-information_sk.pdf)

slovenščina (SL) (597 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/sl/documents/product-information/zolgensma-epar-product-information_sl.pdf)

Suomi (FI) (590.78 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/fi/documents/product-information/zolgensma-epar-product-information_fi.pdf)

svenska (SV) (574.96 KB - PDF)

**First published:**

27/05/2020

**Last updated:**

28/08/2025

[View](/sv/documents/product-information/zolgensma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000289527 27/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zolgensma : EPAR - All authorised presentations

English (EN) (84.84 KB - PDF)

**First published:** 27/05/2020

[View](/en/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-15)

български (BG) (93.62 KB - PDF)

**First published:**

27/05/2020

[View](/bg/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_bg.pdf)

español (ES) (70.14 KB - PDF)

**First published:**

27/05/2020

[View](/es/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81 KB - PDF)

**First published:**

27/05/2020

[View](/cs/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (68.9 KB - PDF)

**First published:**

27/05/2020

[View](/da/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (75.69 KB - PDF)

**First published:**

27/05/2020

[View](/de/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.79 KB - PDF)

**First published:**

27/05/2020

[View](/et/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (89.95 KB - PDF)

**First published:**

27/05/2020

[View](/el/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_el.pdf)

français (FR) (71.76 KB - PDF)

**First published:**

27/05/2020

[View](/fr/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (124.86 KB - PDF)

**First published:**

27/05/2020

[View](/hr/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (74.82 KB - PDF)

**First published:**

27/05/2020

[View](/is/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (74.79 KB - PDF)

**First published:**

27/05/2020

[View](/it/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (92.29 KB - PDF)

**First published:**

27/05/2020

[View](/lv/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.63 KB - PDF)

**First published:**

27/05/2020

[View](/lt/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (84.73 KB - PDF)

**First published:**

27/05/2020

[View](/hu/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (98.32 KB - PDF)

**First published:**

27/05/2020

[View](/mt/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (75.66 KB - PDF)

**First published:**

27/05/2020

[View](/nl/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (77.06 KB - PDF)

**First published:**

27/05/2020

[View](/no/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_no.pdf)

polski (PL) (94.29 KB - PDF)

**First published:**

27/05/2020

[View](/pl/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_pl.pdf)

português (PT) (77.92 KB - PDF)

**First published:**

27/05/2020

[View](/pt/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_pt.pdf)

română (RO) (96.31 KB - PDF)

**First published:**

27/05/2020

[View](/ro/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (99.5 KB - PDF)

**First published:**

27/05/2020

[View](/sk/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (79.33 KB - PDF)

**First published:**

27/05/2020

[View](/sl/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (72.39 KB - PDF)

**First published:**

27/05/2020

[View](/fi/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (78.07 KB - PDF)

**First published:**

27/05/2020

[View](/sv/documents/all-authorised-presentations/zolgensma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zolgensma Active substance onasemnogene abeparvovec International non-proprietary name (INN) or common name onasemnogene abeparvovec Therapeutic area (MeSH) Muscular Atrophy, Spinal Anatomical therapeutic chemical (ATC) code M09AX09

### Pharmacotherapeutic group

Other drugs for disorders of the musculo-skeletal system

### Therapeutic indication

Zolgensma is indicated for the treatment of:

- patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or
- patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.

## Authorisation details

EMA product number EMEA/H/C/004750

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 26/03/2020 Marketing authorisation issued 18/05/2020 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zolgensma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (123.43 KB - PDF)

**First published:** 28/08/2025

[View](/en/documents/procedural-steps-after/zolgensma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zolgensma : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (244.03 KB - PDF)

**First published:** 09/11/2020

**Last updated:** 28/08/2025

[View](/en/documents/procedural-steps-after/zolgensma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Zolgensma-H-C-PSUSA-00010848-202405 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/153669/2025

English (EN) (128.7 KB - PDF)

**First published:** 06/05/2025

[View](/en/documents/scientific-conclusion/zolgensma-h-c-psusa-00010848-202405-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Zolgensma-H-C-PSUSA-00010848-202305 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/86623/2024

English (EN) (129.46 KB - PDF)

**First published:** 26/03/2024

[View](/en/documents/scientific-conclusion/zolgensma-h-c-psusa-00010848-202305-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Zolgensma-H-C-004750-P46-018 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/66683/2022

English (EN) (901.6 KB - PDF)

**First published:** 21/07/2022

[View](/en/documents/variation-report/zolgensma-h-c-004750-p46-018-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Zolgensma : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-2005359794-17637

English (EN) (389.96 KB - PDF)

**First published:** 27/05/2020

[View](/en/documents/orphan-maintenance-report/zolgensma-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Zolgensma : EPAR - Public assessment report

Adopted

Reference Number: EMA/200482/2020

English (EN) (3.5 MB - PDF)

**First published:** 27/05/2020

[View](/en/documents/assessment-report/zolgensma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zolgensma

Adopted

Reference Number: EMA/106773/2020

English (EN) (133.25 KB - PDF)

**First published:** 27/03/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zolgensma_en.pdf)

#### News on Zolgensma

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 February 2021](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-february-2021) 12/02/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020 (updated)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2020-updated) 27/03/2020

[New gene therapy to treat spinal muscular atrophy (corrected)](/en/news/new-gene-therapy-treat-spinal-muscular-atrophy-corrected) 27/03/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Zolgensma : EPAR - Product information - tracked changes

English (EN) (379.82 KB - DOCX)

**First published:** 28/08/2025

[View](/en/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-246)

български (BG) (406.43 KB - DOCX)

**First published:**

28/08/2025

[View](/bg/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_bg.docx)

español (ES) (374.36 KB - DOCX)

**First published:**

28/08/2025

[View](/es/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_es.docx)

čeština (CS) (378.54 KB - DOCX)

**First published:**

28/08/2025

[View](/cs/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (384.75 KB - DOCX)

**First published:**

28/08/2025

[View](/da/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (409.09 KB - DOCX)

**First published:**

28/08/2025

[View](/de/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (381.03 KB - DOCX)

**First published:**

28/08/2025

[View](/et/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (413.48 KB - DOCX)

**First published:**

28/08/2025

[View](/el/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_el.docx)

français (FR) (374.96 KB - DOCX)

**First published:**

28/08/2025

[View](/fr/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (380.59 KB - DOCX)

**First published:**

28/08/2025

[View](/hr/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (406.91 KB - DOCX)

**First published:**

28/08/2025

[View](/is/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_is.docx)

italiano (IT) (361.81 KB - DOCX)

**First published:**

28/08/2025

[View](/it/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (395.07 KB - DOCX)

**First published:**

28/08/2025

[View](/lv/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (350.6 KB - DOCX)

**First published:**

28/08/2025

[View](/lt/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (397.53 KB - DOCX)

**First published:**

28/08/2025

[View](/hu/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (390.57 KB - DOCX)

**First published:**

28/08/2025

[View](/mt/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (398.51 KB - DOCX)

**First published:**

28/08/2025

[View](/nl/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (391.4 KB - DOCX)

**First published:**

28/08/2025

[View](/no/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_no.docx)

polski (PL) (405.27 KB - DOCX)

**First published:**

28/08/2025

[View](/pl/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_pl.docx)

português (PT) (386.98 KB - DOCX)

**First published:**

28/08/2025

[View](/pt/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_pt.docx)

română (RO) (404.27 KB - DOCX)

**First published:**

28/08/2025

[View](/ro/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (418.31 KB - DOCX)

**First published:**

28/08/2025

[View](/sk/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (396.1 KB - DOCX)

**First published:**

28/08/2025

[View](/sl/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (404.61 KB - DOCX)

**First published:**

28/08/2025

[View](/fi/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (385.95 KB - DOCX)

**First published:**

28/08/2025

[View](/sv/documents/product-information-tracked-changes/zolgensma-epar-product-information-tracked-changes_sv.docx)

#### More information on Zolgensma

- [EU/3/15/1509 - orphan designation for treatment of spinal muscular atrophy](/en/medicines/human/orphan-designations/eu-3-15-1509)
- [EMEA-002168-PIP01-17-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002168-pip01-17-m06)
- [Zolgensma - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/zolgensma)
- [Zolgensma - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/zolgensma-0)

#### Topics

- [Advanced therapies](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A42)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/08/2025

## Share this page

[Back to top](#main-content)